References

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

10.1073/pnas.0710370104 · 2007 · External reference

The role of early changes in routine coagulation tests in predicting the occurrence and prognosis of sepsis

10.5847/wjem.j.1920-8642.2025.036 · 2025 · External reference

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

10.1038/ncomms11815 · 2016 · External reference

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

10.1038/s41467-023-35961-y · 2023 · External reference

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

10.1158/2159-8290.cd-14-0337 · 2014 · External reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

10.1126/science.1141478 · 2007 · External reference

Non-Small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in oncology

10.6004/jnccn.2022.0025 · 2022 · External reference

Exon 16-skipping HER2 as a novel mechanism of osimertinib resistance in EGFR L858R/T790M-positive non-small cell lung cancer

10.1016/j.jtho.2019.09.006 · 2020 · External reference

Performance of a novel medical artificial intelligence large language model on supporting decision-making for emergency patients with suspected sepsis

10.5847/wjem.j.1920-8642.2025.095 · 2025 · External reference

EGFR-mutant adenocarcinomas that transform to small cell lung cancer and other neuroendocrine carcinomas: clinical outcomes

10.1200/jco.18.01585 · 2019 · External reference

EGFR mutation incidence in non-small cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)

2015 · External reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

10.1056/nejmoa0810699 · 2009 · External reference

Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer

10.1056/nejmoa1612674 · 2017 · External reference

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small cell lung cancer

10.1038/ncomms7377 · 2015 · External reference

Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes

10.1016/j.jtho.2019.06.002 · 2019 · External reference

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

10.1158/1078-0432.ccr-10-2692 · 2011 · External reference

Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib

10.1001/jamaoncol.2018.2969 · 2018 · External reference

Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

10.1016/j.annonc.2020.08.2100 · 2020 · External reference

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

10.1016/s1470-2045(16)30033-x · 2016 · External reference

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

10.1016/s1470-2045(16)30146-2 · 2016 · External reference

Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study

10.1093/annonc/mdy424.063 · 2018 · External reference

Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC (FLAURA)

10.1056/nejmoa1913662 · 2020 · External reference

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

10.1126/scitranslmed.3002003 · 2011 · External reference

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small cell lung cancer of adenocarcinoma histology (PIONEER)

10.1097/jto.0000000000000033 · 2014 · External reference

Osimertinib in untreated EGFR-mutated advanced non-small cell lung cancer

10.1056/nejmoa1713137 · 2018 · External reference

Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

10.3322/caac.21660 · 2021 · External reference

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

10.1158/2159-8290.cd-12-0108 · 2012 · External reference

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M

10.1038/nm.3854 · 2015 · External reference

Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small cell lung cancer

10.1200/jco.2018.77.7326 · 2018 · External reference

Analysis of tumor specimens at the time of acquired resistance to EGFR TKI therapy in 155 patients with EGFR-mutant lung cancers

10.1158/1078-0432.ccr-12-2246 · 2013 · External reference

Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of mTOR as a mediator of resistance

10.1158/1078-0432.ccr-17-2961 · 2018 · External reference

The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

10.18632/oncotarget.12587 · 2016 · External reference

A predictive model for intracranial hemorrhage in adult patients receiving extracorporeal membrane oxygenation

10.5847/wjem.j.1920-8642.2025.037 · 2025 · External reference